CALQUENCE ® (acalabrutinib, as maleate) ASTRAZENECA HK Reg. No. HK- 68724 (17 Jun, 2025) Composition: 1 • Each hard capsule contains 100 mg of acalabrutinib Indication: 1 • Calquence as monotherapy or in combination with obinutuzumab i...
Hodgkin lymphoma (HL) is a rare B-cell lymphatic malignancy distinguished by its unique histological, immunophenotypic, and clinical characteristics 1,2 . According to the 2022 Hong Kong Cancer Registry data, HL accounts for ~3% of all haematologica...
Prostate cancer (PCa) is one of the most common malignancies in men worldwide, with incidence projected to rise from 1.4 million in 2020 to 2.9 million by 2040 due to aging populations and increased life expectancy 1 . In Hong Kong, PCa was the ...
Multiple myeloma (MM) is one of the most common haematological malignancies with a global incidence ranging from 0.5 to 5 per 100,000 1 . It is characterised by the monoclonal proliferation of malignant plasma cells in the bone marrow, leading to da...
Prostate cancer is primarily screened with the prostate-specific antigen (PSA) test. Recently, scientists have identified a set of protein biomarkers in urine that could detect prostate cancer presence and severity with remarkable precision. These b...
NOTRIXUM ® (pazopanib, as hydrochloride) TEVA HK Reg. No. HK-68611 (13 Mar, 2025) Composition: 3 • Pazopanib is available as 200 mg film-coated tablets Indication: 3 Pazopanib (Teva) is indicated for: • Treatment of advanced and/or met...
IMDELLTRA ® (drug powder vial: tarlatamab; stabilizer solution vial: stabilizer solution) AMGEN HK Reg. No. HK-68549, HK-68550 (17 Jan, 2025) Composition: 3 • For injection: 1 mg of lyophilized powder in a single-dose vial for reconstitutio...
Precision oncology (PO), defined as molecular profiling of tumours to identify targetable alteration 1 . The approach has shifted away from non-specific cytotoxic treatment to a more individualised cancer treatment. The advancement in diagnostic tec...
Multiple myeloma is a clonal plasma cell proliferative disorder that is often diagnosed in individuals aged 65 to 74 years 1 . Notably, the treatment landscape of MM has evolved over the last few years with availability of newer agents and combinati...
Multiple myeloma (MM) is a clonal plasma cell disorder characterised by excess production of monoclonal immunoglobulins and light chains that can ultimately lead to specific end-organ damage 1 . Notably, MM is the second most common haematologic mal...
Prostate cancer (PCa) is a complex disease that affects millions of males, globally. It is the 3rd most common cancer in males and the 4th leading cause of male cancer-related deaths in Hong Kong1. The aetiology of PCa is believed to be related to s...
Hepatocellular carcinoma (HCC) is ranked as the sixth most common cancer worldwide and its incidence has been progressively increasing. HCC is also the third most common cause of cancer-related death, with a 5-year survival rate of just 3% 1 . Inter...
